“Factors Impacting the Establishment of Individual Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts (PDOX) Mouse Models: A UCLA Sarcoma Program Prospective Clinical Trial” by Eckardt et al.
By Tara Russell, MD, MPH UCLA General Surgery Resident This study demonstrates a very high (82%) establishment rate for PDOX in HG-STS patients who were treatment naïve at the time of surgical excision.
Certis Oncology Solutions was formed in 2016 with the mission to provide individualized precision patient care. Our patient-directed therapy enables oncologists to tailor and optimize therapies for patients suffering from aggressive cancers. We also provide pre-clinical services for pharmaceutical and biotech companies. The differentiators for all of our services are the Certis Orthotopic PDX techniques. Certis is affiliated with leading cancer physicians at UCLA and Memorial Sloan Kettering.